The findings highlight specific kinds of changes in lupus biomarkers that are most associated with effective use of belimumab in the treatment of lupus.
The results of this study reveal differences in autoantibody profiles over time in people with lupus, with important ethnicity-related differences, and their relationship to lupus-mediated organ damage over time.
The researchers hoped to learn about the safety and efficacy of atorvastatin (Lipitor®) in reducing cholesterol in children with lupus.
As people with lupus have become increasingly educated about their disease and involved in their medical care, input from patients about their condition has become increasingly important and useful. Recently, the Lupus Damage Index Questionnaire (LDIQ) was developed for this purpose and captures the spectrum of knowledge acquired from the SDI in a patient-reported questionnaire.
For years, researchers have investigated the possibility of inhibiting the actions of lupus-related autoantibodies to reduce the extent of organ damage. Further research in this area has the potential to facilitate the development of new therapies for people with lupus.
Since lupus nephritis can be severe and the therapy can be toxic, it is important to be able to predict which patients would most benefit from long-term treatment.
The researchers hoped to learn whether people with lupus kidney involvement from different races shared the same set of microRNAs.
Current treatments for lupus nephritis in children are toxic and sometimes ineffective. New tests for proteins that might be abnormal in lupus nephritis could help make the diagnosis earlier and might also point to new ways of treating the disease.